Results 21 to 30 of about 221,455 (333)

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Frontiers in Immunology, 2021
Primary membranous nephropathy (pMN) is an autoimmune kidney disease and a common cause of nephrotic syndrome in adults. Rituximab is becoming a first line therapy for patients with persistent nephrotic syndrome with proven safety and efficacy, achieving
Maxime Teisseyre, Maxime Teisseyre, Marion Cremoni, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Sonia Boyer-Suavet, Thomas Crepin, Sylvia Benzaken, Kévin Zorzi, Vincent Esnault, Vesna Brglez, Vesna Brglez, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +15 more
doaj   +1 more source

Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial

Annals of the Rheumatic Diseases, 2023
Objective Following induction of remission with rituximab in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) relapse rates are high, especially in patients with history of relapse.
Rona M. Smith, R. Jones, U. Specks, S. Bond, M. Nodale, R. Al-Jayyousi, J. Andrews, A. Bruchfeld, B. Camilleri, S. Carette, C. Cheung, V. Derebail, T. Doulton, A. Ferraro, Lindsy J. Forbess, S. Fujimoto, S. Furuta, Ora Gewurz-Singer, L. Harper, T. Ito-Ihara, N. Khalidi, R. Klocke, C. Koening, Y. Komagata, C. Langford, P. Lanyon, R. Luqmani, Carol A. McAlear, L. Moreland, K. Mynard, P. Nachman, C. Pagnoux, C. Peh, C. Pusey, D. Ranganathan, Rennie L. Rhee, R. Spiera, A. Sreih, V. Tesař, Giles D. Walters, C. Wroe, D. Jayne, P. Merkel   +42 more
semanticscholar   +1 more source

Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial

European Respiratory Journal, 2023
Background Standard of care for interstitial lung disease (ILD) with a nonspecific interstitial pneumonia (NSIP) pattern proposes mycophenolate mofetil (MMF) as one of the first-step therapies while rituximab is used as rescue therapy.
J. Mankikian, A. Caille, M. Reynaud-Gaubert, M. Agier, Julien Bermudez, P. Bonniaud, R. Borie, P. Brillet, J. Cadranel, I. Court-Fortune, B. Crestani, M. Debray, E. Gomez, A. Gondouin, Sandrine Hirschi-Santelmo, D. Israel-Biet, S. Jouneau, K. Juvin, J. Léger, M. Kerjouan, C. Marquette, J. Naccache, H. Nunes, L. Plantier, G. Prévôt, S. Quêtant, J. Traclet, V. Valentin, Y. Uzunhan, L. Wémeau-Stervinou, T. Bejan-Angoulvant, V. Cottin, S. Marchand-Adam   +32 more
semanticscholar   +1 more source

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

The Lancet Oncology, 2023
BACKGROUND The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludarabine,
P. Hillmen, A. Pitchford, A. Bloor, A. Broom, Moya Young, B. Kennedy, R. Walewska, M. Furtado, G. Preston, J. Neilson, N. Pemberton, G. Sidra, N. Morley, K. Cwynarski, A. Schuh, F. Forconi, N. Elmusharaf, Shankaranarayana Paneesha, C. Fox, D. Howard, A. Hockaday, Julia M. Brown, D. Cairns, Sharon M. Jackson, N. Greatorex, N. Webster, J. Shingles, S. Dalal, P. Patten, D. Allsup, A. Rawstron, T. Munir   +31 more
semanticscholar   +1 more source

Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab

Annals of Allergy, Asthma & Immunology, 2023
Rituximab is a chimeric anti-CD20 monoclonal antibody that targets CD20-expressing B-lymphocytes, has a well-defined efficacy and safety profile, and is broadly used to treat a wide array of diseases.
T. Athni, Sara Barmettler
semanticscholar   +1 more source

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab

Frontiers in Immunology, 2020
Membranous Nephropathy (MN) is an autoimmune disease associated with antibodies against podocyte proteins: M-type phospholipase A2 receptor (PLA2R1) or thrombospondin type-1 domain-containing 7A (THSD7A) in 70 and 3% of patients, respectively.
Sonia Boyer-Suavet, Sonia Boyer-Suavet, Marine Andreani, Maël Lateb, Benjamin Savenkoff, Vesna Brglez, Sylvia Benzaken, Ghislaine Bernard, Patrick H. Nachman, Vincent Esnault, Vincent Esnault, Barbara Seitz-Polski, Barbara Seitz-Polski, Barbara Seitz-Polski   +13 more
doaj   +1 more source

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood, 2022
Shanafelt et al report on the long-term outcome of the pivotal ECOG-ACRIN E1912 study, detailing the continued superiority of ibrutinib plus rituximab (IR) compared to the prior standard treatment—fludarabine, cyclophosphamide and rituximab (FCR)—for ...
T. Shanafelt, X. V. Wang, C. Hanson, E. Paietta, S. O'Brien, J. Barrientos, D. Jelinek, E. Braggio, J. Leis, C. C. Zhang, S. Coutre, P. Barr, A. Cashen, A. Mato, Avina K. Singh, Michael P. Mullane, R. Little, H. Erba, R. Stone, M. Litzow, M. Tallman, N. Kay   +21 more
semanticscholar   +1 more source

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.

The Lancet Respiratory Medicine, 2022
BACKGROUND Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue disease (CTD), but has not been studied in clinical trials.
Toby M. Maher, Veronica A Tudor, P. Saunders, M. Gibbons, S. Fletcher, C. Denton, R. Hoyles, H. Parfrey, E. Renzoni, M. Kokosi, A. Wells, D. Ashby, M. Szigeti, P. Molyneaux   +13 more
semanticscholar   +1 more source

Rituximab

Indian Pediatrics, 2011
Rituximab is a chimeric mouse-human monoclonal antibody against the CD 20 antigen on the surface of B lymphocytes. It binds to CD20 and causes B cell death by antibody dependant cell-mediated cytotoxicity, complement mediated cytotoxicity and apoptosis. It leads to rapid and sustained depletion of B cells.
Anupama, Borker, Narendra, Choudhary
openaire   +3 more sources

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

JAMA Neurology, 2020
Importance Although highly effective disease-modifying therapies for multiple sclerosis (MS) have been associated with an increased risk of infections vs injectable therapies interferon beta and glatiramer acetate (GA), the magnitude of potential risk ...
G. Luna, Peter Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, J. Salzer, A. Svenningsson, M. Vrethem, T. Olsson, F. Piehl, T. Frisell   +15 more
semanticscholar   +1 more source